ESMO 2020: Two-pronged attack using new targeted drug could treat ‘addicted’ prostate cancers

[George71]

icr.ac.uk/news-archive/esmo...

A revolution in our treatment of prostate cancer'

Professor Paul Workman, Chief Executive of the ICR, said:

“We are in the middle of a revolution in our treatment of prostate cancer, with men with the disease now starting to have access to a range of targeted treatments, some of which are tailored for men with particular genetic subtypes.

“This new study shows how a combination of two targeted treatments can cut off cancer’s evolutionary escape routes and keep men with a group of particularly aggressive tumours healthy for longer. It’s a great example of the research we are doing at the ICR to combat cancer evolution and drug resistance – which together represent the biggest challenge we face in improving treatment.”

[MateoBeach]

Thanks for that George. Great brain workout to see how this drug ipatasertib can work via the AKt pathways in those with PTEN mutations. For a tour of the landscape:

en.m.wikipedia.org/wiki/PI3...

Or maybe: cellsignal.com/contents/sci...

Stretches the old brain cells either way!🤣🤣🤣🤷‍♂️